Raf-1 and VEGF signaling pathways play a role in the molecular pathogenesis of HCC, providing a rationale for administering sorafenib to HCC patients, and sorafenib has been the standard of care as the first line therapy for advanced HCC, following a phase III clinical trial showing survival benefits [140]. This evidence concerns the gene RAF1 and hepatocellular carcinoma.